STRUCTURE THERAPEUTICS INC (GPCR)
US86366E1064 - ADR
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.
Could Structure Therapeutics Become the Next Novo Nordisk?
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
The company is focusing on obesity treatment after its glaucoma drug failed.
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Structure Therapeutics has a long way to go before beating Wegovy.
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Qiming's Nisa Leung Made the 2024 Forbes Midas List
/PRNewswire/ -- The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung,...
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.
Monday Sector Leaders: Biotechnology, Drugs
Structure Reports Early Oral Weight-Loss Drug Data Adding Allure
Structure Therapeutics Inc. reported early-stage data on its oral weight-loss drug as the company looks to find a niche in the rapidly growing market.
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity...
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider.
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Structure Therapeutics (NASDAQ:GPCR) just reported results for the first quarte...
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
7 Small-Cap Stocks that Wall Street Loves for Good Reason
As small-cap stocks start to catch up to the market rally, it's time to look at seven small-cap stocks that Wall Street loves.
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Structure Therapeutics (NASDAQ:GPCR) just reported results for the fourth quart...
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company...